Skip to main content

Table 1 IC50 (µM) values and fold decrease in drug sensitivity (RI) of parental (CEM) versus resistant (CEM-VCR R and CEM/2ME2 28.8R) human acute lymphoblastic leukemia cell lines treated with microtubule targeting agents

From: N-alkylisatin-based microtubule destabilizers bind to the colchicine site on tubulin and retain efficacy in drug resistant acute lymphoblastic leukemia cell lines with less in vitro neurotoxicity

IC50 (µM) ± SDa Resistance Index (RI)b
Compound CEM CEM-VCR R CEM/2ME2-28.8R CEM-VCR R:CEM CEM/2ME2-28.8 R:CEM
Vincristine 0.08 (± 0.05) 8.11 (± 1.62) 0.41 (± 0.19) 101.4 < 0.05 5.1 > 0.05
Vinblastine 0.13 (± 0.06) 1.12 (± 0.16) 0.39 (± 0.13) 8.6 < 0.05 3.0 > 0.05
2-Methoxy-estradiol 0.08 (± 0.04) 4.07 (± 1.34) 8.52 (± 1.38) 50.9 < 0.05 106.5 < 0.05
Colchicine 0.32 (± 0.21) 1.01(± 0.36) 0.56 (± 0.19) 3.2 < 0.05 1.8 > 0.05
Paclitaxel 0.15 (± 0.09) 1.11 (± 0.36) 0.25 (± 0.12) 7.4 < 0.05 1.7 > 0.05
HMB-isatin 1.02 (± 0.32) 1.07 (± 0.37) 1.29 (± 0.41) 1.0 > 0.05 1.3 > 0.05
I4M-isatin 1.07 (± 0.44) 1.26 (± 0.19) 1.16 (± 0.46) 1.2 > 0.05 1.1> 0.05
N2M-isatin 0.36 (± 0.19) 0.49 (± 0.36) 0.46 (± 0.32) 1.4 > 0.05 1.3 > 0.05
  1. aValues are the mean of three independent experiments, performed in triplicate (n = 9) ± SD
  2. bThe RI was calculated to determine the degree of acquired resistance of each cell line to the various drug treatments and was determined using the following equation:\(RI = \frac{{IC50 \left( {resistant\,subline} \right)}}{{IC50 \left( {sensitive\,subline} \right)}}\). P-values < 0.05 were considered significant